Donor cell therapy for CD30-positive lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma that is CD30-positive (a marker on the cancer cells).
- You are between 12 and 75 years old.
- Your liver and kidney function are within certain limits (your doctor will check).
- You are not pregnant or breastfeeding, and you agree to use birth control during the study.
- You have recovered from the side effects of any previous chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from your own immune cells, which are modified to find and attack CD30-positive lymphoma cells. It is for people with Hodgkin or non-Hodgkin lymphoma that has come back or not responded to other treatments.
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
This trial tests a new treatment called CD30 CAR-T, which uses your own immune cells to attack lymphoma cells that have the CD30 protein. It is for people whose lymphoma has come back or not responded to at least 2 prior treatments.
Hear when a new Anaplastic Large Cell Lymphoma, ALK-Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.